Let’s take a quick look at GBS. Over the last five years, earnings have fallen by 12.2% each year. Revenue is less than one million dollars ($442K). The stock has been extremely volatile during the last three months. The company’s market capitalization is insignificant ($43 million). Over the last three months, GBS has been more volatile than 75% of US equities, moving +/- 13% each week on average.
GBS is currently developing an in-situ test to give patients an appropriate option for finger-pointing blood glucose detection in diabetes monitoring using the Saliva Glucose biosensor, which is the first invention based on the biosensor platform. As part of its development and market launch plan, GBS (GBS) has released the findings of a study of more than 300 patients globally.
90% of patients in all target markets reacted favorably to the biosensor platform. Diabetes is a global chronic health concern that affects more than 400 million people globally, with the number anticipated to rise to 700 million by 2045. As a result, it’s possible that this company may reward patient investors.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.